<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Increased risk of serious undesirable effects, due to inhibition of the metabolism of the immunomodulator by the ribavirin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
